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The CD2 antigen (Tll, E-rosette receptor) was first identified on human T lym-
phocytes with mAbs (1-3). The antigen is a glycoprotein of 50,000 apparent M, and
recently the protein sequences for CD2 of human (4, 5), rat (6), and mouse (7) have
been derived from cDNA sequences. In each case the sequence indicates two ex-
ternal domains that are Ig related, one transmembrane sequence, and a cytoplasmic
domain with 115-116 amino acids.
In humans, anti-CD2 mAbs were initially found to inhibit T lymphocyte prolifer-
ation stimulated by mitogens, soluble antigens, or allogeneic cells (3, 8-10). Then
particular combinations of antibodies were found to be mitogenic and some single
antibodies also had this property when present with phorbol esters (11-13). CD2 is
expressed in human thymocytes from an early stage and triggering of cell division
by a natural ligand ofCD2 has been suggested as an alternative route for cell activa-
tion to the T lymphocyte antigen receptor (11, 14). There is stong evidence that LFA-3
(alternatively identified as sheep erythrocyte TUTS) is the natural ligand for CD2
(15-17) and that the interaction between CD2 and LFA-3 can mediate adhesion of
lymphoid cells. Also, purified LFA-3 can synergize with anti-CD2 to stimulate mito-
genesis (18).
In the rat, the MRC OX-34 antibody is specific for CD2 and labels most T lym-
phocytes and thymocytes (6, 19). However, OX-34 also labels rat splenic macrophages,
while similar cells in humans have not been reported to be CD2` . The MRC 0X-
34 mAb had no clear-cut effect on the function ofthe T lymphocytes, but has been
recently shown to inhibit the cytolytic function of an NK-like cell line (20).
In the present work we have raised new mAbs against rat CD2 and show that
one pairing of these activates DNA synthesis in T lymphocytes. The response was
dependent on accessory cells and was potentiated by an anti-CD5 mAb and inhibited
by anti-IL-2-R antibody.
Materials and Methods
Animals.
￿
Inbred PVG-RT1` and PVG-RTI° rats (referred to as HO and HO.B2, respec-
tively) were from the Specific Pathogen Free Unit of the MRC Cellular Immunology Unit.
BALB/c mice were from the Sir William Dunn School of Pathology.
Monoclonal and Other Antibodies.
￿
Cloned hybrid cell lines that produce the mAbs MRC
OX-53, OX-54, and OX-55 were from two fusions between mouse spleen cellsand the mouse
myeloma line NSO/l using standard procedures(21). The spleen cells were from BALB/c mice
immunized with purified rat CD2 (6): two 7 wg i .m. injections of CD2 emulsified in CFA
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given on days 0 and 14, followed by one 7 pg i .p. injection of potassium alum precipitate
of the pure CD2. Mice were boosted with either 5 x 10' washed HO thymocytes given in-
travenously on day 56 (MRC OX-53) or with 15 pg of the pure proteingiven intraperitoneally
on day 154(OX-54 andOX-55). MRC OX-53, OX-54, andOX-55 areallof the IgGI isotype.
Other mAbs used (referenced below or in reference 19) were: W3/13, IgGI, anti-rat leu-
kosialin (LSGP); W3/25, IgGI, anti-rat CD4; MRC OX-1, IgGI and MRC OX-30, IgG2a,
against distinct epitopes of the leucocyte common antigen (L-CA)' (22); MRC OX-22,
IgG2a, anti-L-CA, restricted determinant (22); MRC OX-6, IgGI, anti-MHC class II (non-
polymorphic); MRC OX-12, IgG2a, anti-rat is chain; MRC OX-19, IgGI, anti-rat CD5 (Ly-1)
(23); MRC OX-34, IgG2a, anti-rat CD2; MRC OX-39, IgGI and NDS 62 (Tellides, G.,
MJ. Dallman, P.J. Morris, manuscript in preparation), IgGI, both anti-IL-2-R mAbs (24);
MRC OX-21, IgGI, anti-human C3b inactivator, used as a control mAb. Antibodies were
used as tissue culture supernatants or purified IgG and F(ab')2 (25).
Rabbit anti-mouse IgG antibodies (RAM) and their F(ab')2 fragments were prepared and
labeled with fluorescein (RAM-FITC) or 1'251 ('25I-RAM) as described (25). Iodination of
OX-54 and OX-55 mAbs was also as described (25).
Cells.
￿
Cervical lymph nodes, thymuses, and spleens were removedasceptically and teased
with watchmakers' forcepsin ice-cold Dulbecco's A+ B medium (DAB) containing 0.2% BSA.
The cells were filtered through lens tissue, washed twice in DAB/BSA, and resuspended in
RPMI-1640 medium containing 2.5 x 10-5 M 2-ME, antibiotics, and 5% (vol/vol) FCS
(Gibco Ltd., Paisley, Scotland) (RPMI/5% FCS).
Blasts.
￿
Either HO thymocytes, lymph node cells (LNC), or spleen cells were incubated
at 2-5 x 10' cells/ml in RPMI/5% FCS for 72 h at 37°C in a humidified 5% C02 incu-
bator with Con A, used at a final concentration of 5 pg/ml. Cells were harvested, washed
in RPMI/5% FCS, and the blasts were separatedon an Isopaque-Ficoll gradient (Pharmacia
(GB) Ltd., Middlesex, U.K.) and centrifuged at 750g for 20 min at room temperature. Cells
recovered from the interface were washed twice in RPMI/5% FCS.
Tissue Culture.
￿
Allcultures were in 0.2 ml in U-bottomed wells of96-well microtiter plates
at 37°C with 5% C02. Medium was RPMI-1640 plus 5% FCS. Stimulator cells were spleen
cells y-irradiated with a "'Cs source (Gamma Cell 40; Atomic Energy of Canada Ltd.
Kanata, Ontario, Canada) at 0.85 Gy/min to yield a dose of 20 Gy.
Proliferation Assays.
￿
For alloantigen-induced proliferation, a primary MLR was set up by
culturing together 2.5 x 105 HO LNC plus 5 x 105 HO.B2 stimulator cells for a total of
90 h. Forproliferation induced by mAbs 2.5 x 105 HO LNC were cultured with or without
5 x 105 HO stimulator cells for a total of either 72 or 90 h. mAbs were added at the begin-
ning of thecultureperiod and were used as tissue culture supernatant unless otherwise stated.
PMA at 2 ng/ml and IgG RAM or F(ab')2 RAM at 20 gg/ml were also added at the begin-
ning of culture when used. Cultures were pulsed with 0.5 gCi tritiated thymidine (Amer-
sham International, Amersham, U.K.) 18 hbefore harvesting onto glass fiber filters (Whatman
Ltd., Maidstone, U.K.). Results areexpressedas arithmetic meansof quadruplicatecultures
+_ SD.
Generation of CTL and "Cr-release Assay.
￿
Cytotoxic cells were generated in an MLR as
above cultured for 5 d. TheY3 rat myeloma cell line carrying the RTl° MHC antigens (21)
was used as a target to assay the CTL activity. The NSO mouse myeloma cell line (21) was
used as a control target for non-specific killing. Percent "Cr release was calculated using
the formula: percent specific release = 100 x [(experimental release - spontaneous re-
lease)/(maximum release - spontaneous release)).
Nonspecific Killing.
￿
''Cr release was used to measure the effect of mAbs on nonspecific
killing (26). Effector cells were incubated in RPMI/2.5% FCS containing 2 mg/ml carbonyl
iron for 1 h at 37°C in 5% C02. Phagocytic cells were then removed magnetically. Re-
maining cells were washed twice in DAB/BSA, resuspended in RPMI/2.5% FCS, and two-
fold serial dilutions were trade. The NSO mouse myeloma cell line was prelabeled with _"Cr
and used as the target at 10^ cells per well with serial dilutions of effector cells. "Cr release
' Abbreviations used in this paper: Cas, supernatant from Con A-activated rat spleen cells; L-CA, leu-
kocyte common antigen; LNC, lymph node cells; RAM, rabbit anti-mouse IgG antibodies.CLARK ET AL.
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was measured after a 4-h incubation of effectors and targets. The percentage specific "Cr
release was calculated as above.
Immunoprecipitation. HO thymocytes were 1251 surface labeled using the lactoperoxi-
dase/glucose oxidase method. Cell membranes were solubilized in 1% NP-40 and antigens
immunoprecipitated and analyzed as described (27).
Indirect Binding Assays and Antibody Blocking Assays.
￿
These were at 4°C unless otherwise
stated and 5 x 106 cells were incubated with mAbs and 1251-F(ab')2 RAM in successive 60-
min incubations with two washes using DAB/0.25% BSA after each step. The system was
calibrated for molecules of first antibody bound by including labeling of thymocytes with
W3/13 mAb and assuming that 38,000 molecules were bound (25, 28). Competition in in-
direct binding assays was assessed by seeing whether binding was additive when antibodies
were mixed (28).
To directly assess competition between antibodies an 1251-labeled mAb was mixed with an
unlabeled mAb and then the mixture was incubated with 5 x 106 thymocytes for 2 h. Cells
were washed and counted as before (25).
Other Methods.
￿
Labeling for FACS II (Becton Dickinson and Co., Mountain View, CA)
analysis (28); immunoperoxidase labeling on cryostat sections (29). Tissue culture superna-
tant containing IL-2 was obtained as a lectin-free supernatant (Cas) from Con A-activated
rat spleen cells (30). This was nonmitogenic when used alone.
Results
The Nature of the Antigen Recognized by MRC OX-53, OX-54, and OX-55 mAbs.
￿
In
preliminary studies, the new mAbs were shown to have a tissue distribution indis-
tinguishable from that of MRC OX-34. In particular splenic tissue macrophages
were labeled (not shown) as well as most thymocytes and T lymphocytes. Labeling
profiles for the mAbs on lymph node cells and activated T lymphocytes are shown
in Fig. 1, a and b.
To establish that the mAbs were against CD2 sequential immunoprecipitations
were carried out in which solubilized 1251-labeled cell surface molecules were
precleared with OX-34 mAb before immunoprecipitation with the other mAbs. All
the mAbs immunoprecipitated similar bands of 50 x 103 apparent Mr and OX-34
removed the material that could react with the OX-53, 54, and 55 mAbs but not
the CD4 antigen that binds to the W3/25 mAb (Fig 1 c). Furthermore, when L cells
were transfected with rat CD2 cDNA, the transfectants but not the normal L cells
were labeled with MRC OX-34, OX-53, OX-54, and OX-55 mAbs (He Qi; Barclay,
A. N., and A. F. Williams, unpublished data) . Thus, there is no doubt that the four
antibodies all bind to CD2 .
Site Numbersfor mAb Binding.
￿
Table I shows the molecules per cell for each anti-
CD2 mAb binding at saturation to resting and blast cells derived from the thymus
or lymph node. The antibodies bound in roughly similar amounts with differences
that might be accounted for by differences in the proportion ofbivalent/monovalent
binding. Although saturating binding was similar the level of antibody needed for
saturation was 10-fold greater for OX-54 and OX-55 antibodies than for OX-34 or
OX-53. Such a difference is unusual and whether or not this might be due to differ-
ences in kinetics of binding remains to be established.
Between T blasts and resting cells, the increment in binding was about threefold.
The volume of T blasts is about three to five times greater than resting T cells, and
thus therewas no increase in antigen density detected between resting and activated
cells.
Competition BetweenmAbs.
￿
Initially, competition was assessed using saturating in-1864
￿
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FIGURE 1 .
￿
FRCS analysis of labeling of (a) HO LNC and (b) 3-d Con A HO LN blasts with
MRC OX-34, OX-53, OX-54, and OX-55 . Cells were labeled with mAb IgG at 20 pg/ml (0X-
34, OX-53) and 100 pg/ml (OX-54, OX-55) at 4°C, followed by RAM-FITC . Fluorescence histo-
grams were obtained on a Becton Dickinson & Co. FAGS II . 104 cells were analyzed for each
profile with cell number shown on a linear scale . Labeling with MRC OX-21 is shown as a nega-
tive control for each cell type (dotted line) . (c) Analysis of the antigen recognized by anti-CD2
mAbs by immunoprecipitation . Lysed HO thymocytes surface labeled with 1251 were incubated
with anti-CD2 mAbs after preclearing ofthe lysate with either an irrelevant mAb or withMRC
OX-34 . Immunoprecipitated material was analyzed using 10% SDS-PAGE, and visualized with
autoradiography . Separate experiments were carried out, with CD2 depletion being assessed by
immunoblotting . The results were as with 1251 labeling, except that OX-55 gave an extra dis-
tinct band at a slightly lower mol wt than that ofauthentic CD2 . Preclearing with neither OX-34
nor OX-55 mAbs removed this band, which is thus thought to be due to artifactual binding .
direct bindingassays with mixtures ofmAbs added in the first step . In other studies,
mAbs against separate molecules or against nonoverlapping epitopes on the same
molecule have given additive bindingwhen mixed in the indirect binding assay(28) .
An exampleofthis is shown for noncompeting mAbs against L-CA (OX-1 and0X-
30) in Table II . In the case ofthe anti-CD2 mAbs, OX-34 and OX-53 are concluded
to be fully competitive since they showed no additive binding at all. With combina-TABLE I
Quantitation of mAb Binding to Thymocytes and T Blasts al Saturation
5 x 106 cells were incubated for 2 h with saturating levels of mAbs, washed,
and then incubated with 0.6 Vg 1251-F(ab')2 RAM (5 x 105 cpm) per assay.
Specific binding was determined and from this molecules of mAb bound were
calculated via calibration of the assay with W3/13 mAb, which is known to bind
at a level of 38,000 molecules per rat thymocyte (25, 28). Similar results were
obtained in two other experiments.
tions of OX-34, OX-54, and OX-55 mAbs partial addition was seen, but this was
considerably less than expected for complete independence of epitopes.
To further check competition between mAbs, direct binding with 1251-OX-54 or
1251-OX-55 was assayed with the results shown in Fig. 2. With this assay no com-
petition was seen between OX-34 and either ofthe mAbs. Between OX-54 and 0X-
55 there was competition, in that OX-54 gave at least partial blocking ofOX-55 but
no inhibition was seen in the opposite direction. Competition between OX-54 and
OX-55 was also assayed in the presence of an excess of OX-34 (since this inhibits
the functional effect of OX-54 plus OX-55, see below), and in these conditions the
results were essentially the same as in Fig. 2 except that OX-54 gave somewhat better
inhibition of OX-55 than that shown in Fig 2 b.
The clear-cut lack of competition in all cases except for OX-54 versus OX-55 is
in apparent contradictionto the partialaddition seenin the saturating bindingassays
(Table II). This might be explained by the fact that ifantibodies are closelyjuxta-
TABLE II
Additive Binding to HO Thymocytes with Mixtures of mAbs under Saturating Conditions
OX-1 OX-30
Control
None
￿
114,316 ± 7,642
￿
86,478 ± 3,335
OX-1
￿
-
￿
182,338 t 13,093
CLARK ET AL.
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5 x 106 washed thymocytes were incubated with 10 ul of each mAb used as purified IgG. Saturating con-
centrations for each mAb had been previously determined. After three washes the cells were incubated with
0.6 ug 1251-F(ab')2 RAM (106 cpm) per assay for 1 h. The cells were washed and cell-bound radioactivity
was determined.
mAbs Thymocytes Thymic
Target
blasts
Cell
LN T cells LN T blasts
OX-34 1 .1 x 104 3.6 x 104 1 .4 x 104 4.7 x 104
OX-53 7.0 x 10' 2.5 x 104 9 .0 x 10" 2 .9 x 104
OX-54 1 .4 x 104 1 .8 x 104 1 .4 x 104 2.1 x 104
OX-55 6.0 x 10' 2.3 x 104 5.0 x 10 3 3.3 x 104
Second mAb OX-34
First
OX-53
mAb
OX-54 OX-55
None 24,107 ± 1,236 24,569 t 2,472 23,723 t 1,713 23,875 ± 823
OX-34 - 25,052 ± 854 33,004 ± 3,202 31,768 t 2,348
OX-54 - - - 36,195 t 2,114
OX-34 +OX-54 - - - 41,586 ± 2,4751866
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FIGURE 2.
￿
Blocking of binding of 12'1 anti-CD2 mAbs. Binding of WI-OX-54 (a) or 12'I-OX-
55 (b) to 5 x IOh thymocytes in the presence of varying amounts of OX-34 (---C~-), OX-54
and OX-55 (--o-) was determined. Cells were incubated with the mAb combinations for 2 h
at 4°C. After two washes the radioactivity bound was counted and the percentage oflabeled mAb
bound was calculated.
posed on a target antigen the level of second antibody that can bind may be less
per molecule than with each antibody added alone.
The Effect of MRC OX-54 and OX-55 on Rat Lymphoid Cell Proliferation.
￿
None of
the anti-CD2 mAbs used alone, either in the presence or absence ofCas, were able
to stimulate DNA synthesis in HO LNC or thymocytes (Fig. 3, a and b) . However,
if MRC OX-54 and OX-55 were used together in the presence of Cas, low but
significant levels of thymidine incorporation were seen with the LNC (Fig. 3 a). In
some experiments the two antibodies with no additional Cas were sufficient to pro-
duce some incorporation, but this result was variable. Thymocytes did not respond
to the two mAbs even in the presence of Cas.
Some variation in results might have been due to variable levels of accessory cells
and Fig. 3 c and d, show that addition of 5 x 105 irradiated syngeneic spleen cells1867
FIGURE 3 .
￿
Effect of accessory cells on proliferative response ofLNC and thymocytes to anti-
CD2 mAbs . HO LNC or thymocytes (2.5 x 105) were incubated either without (a, b) or with
(c, d) 5 x 105 irradiated syngeneic spleen cells for 72 h in RPMI/5°Jo FCS. mAbs were added
at the beginning of culture as tissue culturesupernatant . Cells were cultured in theabsence (solid
columns) or presence (cross hatched columns) of 10% Cas.
considerably stimulated the response of both LNC and thymocytes . The anti-CD2
mAbs used singly still gave no proliferation but the combination ofMRC OX-54
and OX-55 caused proliferation in both cell types thatwasnot significantly enhanced
by the addition ofCas. No other combination of anti-CD2 mAbs gave stimulation
even in the presence of accessory cells .
The effect of other mAbs on stimulation of cells by OX-54 and OX-55 was exam-
ined and the results were contrasted with the effects of the same antibodies on the
MLR. OX-19 (anti-CD5) is known to stimulate the MLR (23) and this also stimu-
lated theC132-mediated proliferation (Fig . 4 a) . The quantitative effect was reprodu-
cibly greater for the CD2 proliferation system than for the MLR.
mAbs against class II MHC, CD4, and the IL-2-R are all known to inhibit the
MLR asshown in Fig . 4 d . In theCD2 system, the anti-class II mAbwasineffective
while the anti-CD4 antibody was inhibitory, but not in the form of F(ab')2, which
does however inhibit the MLR. The anti-IL-2-R antibody also inhibited the C132-
mediated proliferation .
In studies on human cells anti-CD2 mAbs can inhibit the MLR, but this is not
reproducibly seen in the rat . The result shown in Fig . 4 d is one where inhibition
with the OX-34 anti-CD2 mAb was seen . In contrast to variable inhibition in the
MLR the OX-34 and OX-53 mAbs reproducibly gave strong inhibition of prolifera-
tion induced by OX-54 and OX-55 . This occurred despite the fact that OX-34 did
not inhibit the binding ofOX-54 or OX-55 (Fig . 2) and that competition between
OX-54 and OX-55 was not effected by binding of OX-34 at the levels used in the
functional assays (data not shown) .1868
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FIGURE 4.
￿
Factors affecting LNC proliferation. (a) 2.5 x 10' HO LNC induced to proliferate
by mAbs MRC OX-54+OX-55 in the form of tissue culture supernatant, in the presence of 5
x 10,5 irradiated HO spleen cells. (b) 2.5 x 10' HO LNC induced to proliferate by 5 x 10' HO.B2
irradiated spleen cells in an allogeneic MLR. Additional mAbs were added to the cells at the
beginning of incubation and the effects ofthese on proliferation studied by measuring ["H)thymi-
dine incorporation. Additional mAbs were used in the form ofeither tissue culture supernatant
or purified IgG or F(ab')2 at 20 ug/ml. Incubation was for 72 h in RPMI/5% FCS (a, c)
and for 90 h (b, d).
In studies on human T cells there are some cases where DNA synthesis is stimu-
lated by one anti-CD2 antibody plus phorbol ester (11, 12). Using PMA at a concen-
tration of2 ng/ml it was found that none ofthe anti-rat CD2 mAbs used singly would
give proliferation with PMA (Fig. 5, a and b). Higher levels of PMA were toxic for
rat T cells. Furthermore, PMA did not augment the proliferation induced by MRC
OX-54 and OX-55 used together. The effects of crosslinking the single mAbs with
either RAM IgG or RAM F(ab')2 were also investigated. No single mAbs were
found to be mitogenic with either crosslinker, even in the presence of PMA. How-
ever, although proliferation induced by MRC OX-54 and OX-55 was not affected
by the addition of RAM IgG, the addition of RAM F(ab')2 prevented almost all
[3H]thymidine incorporation. These results were unaffected by the presence or ab-
sence of PMA. The inhibition with F(ab')2 RAM may occur because interaction
with Fc receptors on accessory cells is essential for the response to occur. F(ab')2
RAM may obscure the Fc of the mAbs without providing its own Fc for interaction,
as would be the case with the use of IgG RAM.
Effect ofAnti-CD2 mAbs on Natural Killing and CTL-mediated Killing.
￿
None of the
anti-CD2 mAbs either singly or in combination had any effect on nonspecific killing
when the NSO mouse myeloma cell line was used as a target for HO spleen cells.
This was also true for the specific CTL-mediated killing of Y3 myeloma cells by
CTL generated in a primary MLR (data not shown) .
Discussion
Stimulation ofmitogenesis in T lymphocytes can be initiated by a variety of mAbs
reacting with molecules not known to be associated with the TCR complex. The
target antigens include Thy-1 and LY-6 in the mouse (31, 32) and CD2 (12, 13), leu-
kosialin (sialophorin) (33), and CD28 (T44) (34) in humans. The results herein showa
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￿
Effect ofcrosslinking andPMAon proliferationof LNC inducedby anti-CD2 mAbs.
2.5 x 105HO LNC plus 5 x 10 HO-irradiatedspleen cells were incubatedwith anti-CD2 mAbs
in the (a) absence or (b) presence of PMA at 2 ng/ml. Crosslinking was performed with either
RAM-IgG or RAM-F(ab')2 at 20 Wig/ml, added at the beginning of incubation, which was for
72 h in RPMI/5% FCS.
that CD2 can also be a mitogenic target for rat T lymphocytes. The requirements
were that the OX-54 and OX-55 mAbs were present along with an undefined popu-
lation of accessory cells. It seemed likely that the accessory cells were required for
more than the crosslinking ofthe mAbs, since crosslinking with F(ab')2 RAM in-
hibited the response possibly by masking Fc determinants (see Results). Phorbol
ester did not potentiate the response or allow stimulation via one mAb.
The MRC OX-54 and OX-55 mAbs showed a curious pattern of competitive
binding, in that OX54 could substantially blockOX-55 binding but the reverse sit-
uation did not occur. As both antibodies were effective in immunoprecipitation it
seemed unlikely that this was due to differences in affinity, andOX-55 did not block
OX-54bindingeven ifcellswere preincubated with theOX-55 mAb (data not shown).
This phenomenon is similar to that seen in crossblocking between the anti-human
CD2 mAbs GT2 and anti-D66 (35), which also synergise to stimulate DNA syn-
thesis. The OX-34 and OX-53 mAbs did not show any blocking ofOX-54 and 0X-
55 binding, yet these mAbs inhibited the stimulatory effects of OX-54 and OX-55.
This is a curious result given that crosslinking ofOX-34 on an NK-like cell line can
trigger release of Ca2+ and turnover of inositol phosphates (20).
The rat CD2 triggering data seems quite similar to the human work with the ex-
ception that: (a) alltheratCD2 determinants so fardescribed areexpressedon resting
and activated cells whereas in humans the CD2 T113 epitope is thought to be specific
to activated cells (11); (b) synergism ofone CD2 mAb and phorbol ester to trigger
the cells is not seen in the rat; (c) accessory cells are thus far essential for triggering
the rat cells; (d)the anti-CD2 mAbsare not inhibitors ofspecific ornonspecificcytoxic
cells, although the OX-34 mAb sometimes shows inhibition of the MLR and has
been shown to block killing by an NK-like cell line (20).
In humans, CD2 has been suggested as a target for stimulation ofT cells by a1870
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pathway that is independent of TCR triggering with a particular role in thymopoi-
esis (14) . DNA synthesis can be triggered in rat thymocytes by the anti-CD2 mAbs,
but it remains to be seen whether the activity is due only to thymocytes of im-
munocompetent phenotype .
Summary
Rat T cells and thymocytes were induced to proliferate by a pair ofmAbs, MRC
OX-54 and MRC OX-55, directed against rat CD2 . Accessory cells were required
but their role was not simply for crosslinking of the two mAbs, as neither MRC
OX-54 nor MRC OX-55 alone, in the presence of a crosslinking second antibody,
caused T cell mitogenesis . Nor could the phorbol ester PMA replace either anti-
body . The two mAbs recognized distinct epitopes on rat CD2 ; however, MRC 0X-
54 could partially blockMRC OX-55 binding whereas the reverse situation was not
seen . A further CD2 epitope was recognized by two mutually competitive mAbs,
MRC OX-34 and MRC OX-53, which were not mitogenic . NeitherMRC OX-34
nor MRC OX-53 affected the binding ofMRC OX-54 orMRC OX-55, yet they
prevented the mitogenic effect induced by these mAbs . The presence ofmAbs against
CD4 and the IL-2-R also abrogated this mitogenesis, whereas an anti-CD5 mAb
augmented the CD2-induced proliferation .
Our thanks to Maggie Dallman for the kind donation ofthe anti-IL-2-R mAb, Stan Bucking-
ham and Catherine Lee for photography, and Denise Roby for typing the manuscript .
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